Announcements
Phosphate supplements in BNF 52
The dose of phosphate in critically ill patients shown in the notes on
phosphate supplements on p499 of BNF 52 has the incorrect units specified.
The dose should read: “In critically ill patients, the dose of
phosphate can be increased up to 500 micromol/kg (approx. 30 mmol in
adults), infused over 6–12 hours, according to severity.” The
error will be corrected in BNF 53 (March 2007).
Trasylol
Bayer Healthcare has written to health care professionals to inform them
of new prescribing advice relating to Trasylol (aprotinin). Trasylol
is now only indicated for prophylactic use to reduce blood loss and
blood transfusion in those patients undergoing cardiopulmonary bypass
in the course of coronary artery bypass graft surgery, who are at increased
risk of blood loss or blood transfusion. Renal dysfunction could be
triggered by aprotinin, particularly in patients with pre-existing
renal dysfunction. In clinical studies, the majority of cases of post-operative
renal dysfunction were not severe and were reversible. However, oliguria,
acute renal failure and renal tubular necrosis have been reported uncommonly
(< 1/100). Careful consideration to the balance of risks and benefits
should be given before administering aprotinin, especially to patients
at known risk of renal dysfunction (for example those taking nephrotoxic
drugs). |
The
Pharmaceutical Journal